Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Accumulated Expenses (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Accumulated Expenses readings, the most recent being $629000.0 for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 93.38% to $629000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $629000.0, a 93.38% decrease, with the full-year FY2025 number at $1.8 million, down 70.17% from a year prior.
  • Accumulated Expenses hit $629000.0 in Q1 2026 for Atara Biotherapeutics, down from $1.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $19.0 million in Q4 2023 to a low of $629000.0 in Q1 2026.
  • Median Accumulated Expenses over the past 5 years was $8.1 million (2024), compared with a mean of $9.8 million.
  • Biggest five-year swings in Accumulated Expenses: soared 196.29% in 2022 and later plummeted 93.38% in 2026.
  • Atara Biotherapeutics' Accumulated Expenses stood at $17.7 million in 2022, then increased by 7.63% to $19.0 million in 2023, then tumbled by 68.29% to $6.0 million in 2024, then tumbled by 70.17% to $1.8 million in 2025, then plummeted by 65.02% to $629000.0 in 2026.
  • The last three reported values for Accumulated Expenses were $629000.0 (Q1 2026), $1.8 million (Q4 2025), and $2.6 million (Q3 2025) per Business Quant data.